Furthermore, since we focussed primarily on anti-IL-1α’s effects on inflammatory outcomes using an acute model, it would be interesting to assess the impact of treatment timing and withdrawal on lung function decline and the response to infection in long-term models of cigarette smoke exposure, as this would more closely recapitulate COPD pathology. The gene discussed is IL1A; the disease is chronic obstructive pulmonary disease.